LGND:NASDAQLigand Pharmaceuticals Incorporated Analysis

Ligand Pharmaceuticals is trading at $293.99, roughly 5.9% above the DCF‑derived fair value of $182.8. The stock sits below its 20‑day SMA of 304.08 but remains above the 50‑day and 200‑day averages, indicating a mixed short‑term bias. The MACD histogram is negative and the MACD signal is bearish, while the RSI of 52 suggests neutral momentum. Volume trends are decreasing, which may limit upside in the near term. Nonetheless, the broader market sentiment is extremely greedy (Fear‑Greed Index 89.93), supporting bullish bias.
14.1% revenue growth with an 83% gross margin and a 33.6% operating margin underscores strong profitability. The company generated $142.1 M of free cash flow and holds $779.4 M in cash against $452 M of debt, yielding a modest debt‑to‑equity of 45%. Forward EPS is projected at $11.60, a 56% increase versus trailing EPS of $7.45, reflecting robust earnings upside. Recent acquisition of XOMA Royalty adds seven commercial products and over 100 development assets, expanding the pipeline and revenue base. Analyst consensus is a “strong buy” with a median target of $309.5, implying limited upside of ~5‑6% from current levels. The P/E of 39.5 is well above the industry average of 28.7, indicating the stock is priced for growth rather than value. Given the high 30‑day volatility of 39% and a beta below 1, the equity carries elevated market risk but is less sensitive to broader moves.